These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12081616)

  • 41. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
    Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
    Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessing product bioequivalence for extended-release formulations and drugs with long half-lives.
    Gehring R; Martinez M
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():3-9. PubMed ID: 22413786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
    Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
    Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The new European Medicines Agency guideline on the investigation of bioequivalence.
    Morais JA; Lobato Mdo R
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):221-5. PubMed ID: 20070293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Introduction to the bioequivalence theme issue.
    Martinez MN; Hunter RP
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():1-2. PubMed ID: 22413785
    [No Abstract]   [Full Text] [Related]  

  • 46. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference.
    Chen ML; Blume H; Beuerle G; Davit B; Mehta M; Potthast H; Schug B; Tsang YC; Wedemeyer RS; Weitschies W; Welink J
    Eur J Pharm Sci; 2018 Jan; 111():153-157. PubMed ID: 28964950
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bioequivalence study designs for generic solid oral anticancer drug products: scientific and regulatory considerations.
    Kaur P; Chaurasia CS; Davit BM; Conner DP
    J Clin Pharmacol; 2013 Dec; 53(12):1252-60. PubMed ID: 23996908
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bioequivalence assessment: a pharmaceutical industry perspective.
    Godbillon J; Cardot JM; Lecaillon JB; Lefevre G; Sioufi A
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):153-8. PubMed ID: 8839689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics and pharmacodynamics of stereoisomeric drugs with particular reference to bioequivalence determination.
    Lees P; Hunter RP; Reeves PT; Toutain PL
    J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():17-29. PubMed ID: 22413788
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Responsible extra-label use of drugs.
    Cobb DV
    J Am Vet Med Assoc; 1996 Nov; 209(9):1545. PubMed ID: 8899012
    [No Abstract]   [Full Text] [Related]  

  • 53. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
    Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
    Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bioequivalence/bioavailability retention samples.
    Ransom C
    Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218
    [No Abstract]   [Full Text] [Related]  

  • 55. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
    Borgheini G
    Clin Ther; 2003 Jun; 25(6):1578-92. PubMed ID: 12860486
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.
    Li Z; Fang L; Jiang W; Kim MJ; Zhao L
    Curr Neurol Neurosci Rep; 2017 Sep; 17(11):82. PubMed ID: 28929357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulatory Considerations for the Approval of Drugs Against Histomoniasis (Blackhead Disease) in Turkeys, Chickens, and Game Birds in the United States.
    Regmi PR; Shaw AL; Hungerford LL; Messenheimer JR; Zhou T; Pillai P; Omer A; Gilbert JM
    Avian Dis; 2016 Dec; 60(4):725-730. PubMed ID: 27902913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report.
    Chen ML; Shah VP; Crommelin DJ; Shargel L; Bashaw D; Bhatti M; Blume H; Dressman J; Ducharme M; Fackler P; Hyslop T; Lutter L; Morais J; Ormsby E; Thomas S; Tsang YC; Velagapudi R; Yu LX
    Eur J Pharm Sci; 2011 Nov; 44(4):506-13. PubMed ID: 21946259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.